XENON PHARMACEUTICALS INC. Investing Cash Flow
XENON PHARMACEUTICALS INC. (XENE) reported Investing Cash Flow of -$738.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$331.24M, a 502.67% decline year-over-year.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$407.28M, a 1280.19% decline year-over-year.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $62.70M, a 36.35% decline year-over-year.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $38.53M, a 7637.15% increase year-over-year.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2025 was $218.00M, a 32.12% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2024 was $165.00M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2023 was -$111.39M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities for fiscal 2022 was -$293.40M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$331.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$738.52M 10-Q · filed 2026-08-06 | -$675.82M derived: sum of 3 quarters · filed 2026-08-06 | -$637.29M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$407.28M 10-Q · filed 2026-05-07 | -$344.58M derived: sum of 2 quarters · filed 2026-05-07 | -$306.05M derived: sum of 3 quarters · filed 2026-05-07 | -$223.79M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $62.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $101.23M derived: sum of 2 quarters · filed 2026-02-26 | $183.49M derived: sum of 3 quarters · filed 2026-08-06 | $218.00M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $38.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $120.79M derived: sum of 2 quarters · filed 2026-08-06 | $155.30M 10-Q · filed 2025-11-03 | $253.80M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $82.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $116.77M 10-Q · filed 2026-08-06 | $215.27M derived: sum of 3 quarters · filed 2026-08-06 | $215.77M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $34.51M 10-Q · filed 2026-05-07 | $133.01M derived: sum of 2 quarters · filed 2026-05-07 | $133.51M derived: sum of 3 quarters · filed 2026-05-07 | $242.70M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $98.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $99.00M derived: sum of 2 quarters · filed 2026-02-26 | $208.19M derived: sum of 3 quarters · filed 2026-02-26 | $165.00M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $498.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $109.69M derived: sum of 2 quarters · filed 2025-11-03 | $66.50M 10-Q · filed 2025-11-03 | -$173.29M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $109.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $66.00M 10-Q · filed 2025-08-11 | $64.52M 10-Q · filed 2024-08-08 | -$173.79M derived: sum of 3 quarters · filed 2026-02-26 | -$119.91M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | -$43.19M 10-Q · filed 2025-05-12 | -$46.20M 10-Q · filed 2024-05-09 | -$282.98M derived: sum of 2 quarters · filed 2026-02-26 | -$229.10M derived: sum of 3 quarters · filed 2026-02-26 | -$201.20M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | -$239.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$185.91M derived: sum of 2 quarters · filed 2026-02-26 | -$158.01M derived: sum of 3 quarters · filed 2026-02-26 | -$111.39M 10-K · filed 2026-02-26 | -$117.17M 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $53.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $81.78M derived: sum of 2 quarters · filed 2024-11-12 | $128.41M 10-Q · filed 2024-11-12 | $122.56M 10-Q · filed 2023-11-08 | $116.67M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $27.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $74.52M 10-Q · filed 2024-08-08 | $62.79M derived: sum of 3 quarters · filed 2025-02-27 | -$171.31M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $46.62M 10-Q · filed 2024-05-09 | $34.88M derived: sum of 2 quarters · filed 2025-02-27 | -$199.21M derived: sum of 3 quarters · filed 2025-02-27 | -$197.90M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$11.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$245.83M derived: sum of 2 quarters · filed 2025-02-27 | -$244.52M derived: sum of 3 quarters · filed 2025-02-27 | -$293.40M 10-K · filed 2025-02-27 | -$296.00M 10-K · filed 2023-03-01 | |||
| 2022-09-30 | -$234.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$232.78M derived: sum of 2 quarters · filed 2023-11-08 | -$281.67M 10-Q · filed 2023-11-08 | -$497.10M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$47.57M 10-Q · filed 2023-08-09 | -$263.00M derived: sum of 3 quarters · filed 2024-02-29 | -$247.43M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | -$48.89M 10-Q · filed 2023-05-09 | -$264.32M derived: sum of 2 quarters · filed 2024-02-29 | -$248.75M derived: sum of 3 quarters · filed 2024-02-29 | -$240.55M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | -$215.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$199.86M derived: sum of 2 quarters · filed 2024-02-29 | -$191.67M derived: sum of 3 quarters · filed 2024-02-29 | -$246.77M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | $15.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $23.77M derived: sum of 2 quarters · filed 2022-11-08 | -$31.34M 10-Q · filed 2022-11-08 | $11.86M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $8.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$46.91M 10-Q · filed 2022-08-09 | -$3.71M derived: sum of 3 quarters · filed 2023-03-01 | -$21.75M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | -$55.10M 10-Q · filed 2022-05-10 | -$11.90M derived: sum of 2 quarters · filed 2023-03-01 | -$29.94M derived: sum of 3 quarters · filed 2023-03-01 | -$19.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $43.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $25.17M derived: sum of 2 quarters · filed 2023-03-01 | $36.10M derived: sum of 3 quarters · filed 2023-03-01 | -$16.82M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | -$18.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$7.10M derived: sum of 2 quarters · filed 2021-11-10 | -$60.02M 10-Q · filed 2021-11-10 | -$120.34M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $10.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$41.99M 10-Q · filed 2021-08-11 | -$102.31M derived: sum of 3 quarters · filed 2021-08-11 | -$94.57M derived: sum of 4 quarters · filed 2021-08-11 | ||||
| 2020-03-31 | -$52.92M 10-Q · filed 2021-05-11 | -$113.24M derived: sum of 2 quarters · filed 2021-05-11 | -$105.50M derived: sum of 3 quarters · filed 2021-05-11 | -$112.13M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | -$60.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$52.58M derived: sum of 2 quarters · filed 2021-03-01 | -$59.21M derived: sum of 3 quarters · filed 2021-03-01 | -$66.21M 10-K · filed 2021-03-01 | -$66.29M 10-K · filed 2020-03-09 | |||
| 2019-09-30 | $7.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.11M derived: sum of 2 quarters · filed 2020-11-05 | -$5.89M 10-Q · filed 2020-11-05 | -$6.03M 10-Q · filed 2019-11-05 | -$18.45M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-06-30 | -$6.63M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2020-08-06 | -$13.63M 10-Q · filed 2020-08-06 | -$13.77M 10-Q · filed 2019-08-06 | -$26.19M derived: sum of 3 quarters · filed 2020-08-06 | -$49.53M derived: sum of 4 quarters · filed 2020-08-06 | |||
| 2019-03-31 | -$7.00M 10-Q/A · filed 2020-05-26 | -$7.03M 10-Q · filed 2019-05-07 | -$19.56M derived: sum of 2 quarters · filed 2020-05-26 | -$42.91M derived: sum of 3 quarters · filed 2020-05-26 | -$40.97M derived: sum of 4 quarters · filed 2020-05-26 | |||
| 2018-12-31 | -$12.56M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | -$35.90M derived: sum of 2 quarters · filed 2020-03-09 | -$33.96M derived: sum of 3 quarters · filed 2020-03-09 | -$28.99M 10-K · filed 2020-03-09 | ||||
| 2018-09-30 | -$23.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$21.41M derived: sum of 2 quarters · filed 2019-11-05 | -$16.43M 10-Q · filed 2019-11-05 | -$10.63M derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $6.92M 10-Q · filed 2019-08-06 | $12.72M derived: sum of 3 quarters · filed 2019-08-06 | $12.63M derived: sum of 4 quarters · filed 2019-08-06 | ||||
| 2018-03-31 | $4.98M 10-Q · filed 2019-05-07 | $10.78M derived: sum of 2 quarters · filed 2019-05-07 | $10.69M derived: sum of 3 quarters · filed 2019-05-07 | |||||
| 2017-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $5.71M derived: sum of 2 quarters · filed 2019-03-06 | $24.29M 10-K · filed 2019-03-06 | |||||
| 2017-09-30 | -$89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $18.49M 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | $18.58M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |